These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29559480)

  • 1. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study.
    Cottereau AS; Versari A; Luminari S; Dupuis J; Chartier L; Casasnovas RO; Berriolo-Riedinger A; Menga M; Haioun C; Tilly H; Tarantino V; Federico M; Salles G; Trotman J; Meignan M
    Blood; 2018 May; 131(22):2449-2453. PubMed ID: 29559480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).
    Luminari S; Biasoli I; Versari A; Rattotti S; Bottelli C; Rusconi C; Merli F; Spina M; Ferreri AJ; Zinzani PL; Gallamini A; Franceschetto A; Boccomini C; Franceschetti S; Salvi F; Raimondo FD; Carella AM; Micol Q; Balzarotti M; Musto P; Federico M
    Ann Oncol; 2014 Feb; 25(2):442-7. PubMed ID: 24412823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. End of induction [
    Guerra L; Chauvie S; Fallanca F; Bergesio F; Marcheselli L; Durmo R; Peano S; Franceschetto A; Monaco L; Barbieri E; Ladetto M; Musuraca G; Tosi P; Bianchi B; Bolis SAM; Pavone V; Chiarenza A; Arcari A; Califano C; Bari A; Massaia M; Conconi A; Musto P; Mannina D; Roti G; Galimberti S; Gini G; Falcinelli F; Vitolo U; Usai SV; Stefani PM; Ibatici A; Liberati AM; Pennese E; Perrone T; Versari A; Luminari S;
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3311-3321. PubMed ID: 38795120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
    Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
    Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.
    Cottereau AS; Rebaud L; Trotman J; Feugier P; Nastoupil LJ; Bachy E; Flinn IW; Haioun C; Ysebaert L; Bartlett NL; Tilly H; Casasnovas O; Ricci R; Portugues C; Buvat I; Meignan M; Morschhauser F
    Ann Oncol; 2024 Jan; 35(1):130-137. PubMed ID: 37898239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.
    Meignan M; Cottereau AS; Versari A; Chartier L; Dupuis J; Boussetta S; Grassi I; Casasnovas RO; Haioun C; Tilly H; Tarantino V; Dubreuil J; Federico M; Salles G; Luminari S; Trotman J
    J Clin Oncol; 2016 Oct; 34(30):3618-3626. PubMed ID: 27551111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic tumor burden on baseline
    Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.
    Wong-Sefidan I; Byrtek M; Zhou X; Friedberg JW; Flowers CR; Zelenetz AD; Dawson KL; Reid E
    Leuk Lymphoma; 2017 Apr; 58(4):809-815. PubMed ID: 27562750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
    Dixon JG; Dimier N; Nielsen T; Zheng J; Marcus R; Morschhauser F; Evens AM; Federico M; Blum KA; Shi Q
    Br J Haematol; 2022 Jul; 198(2):333-337. PubMed ID: 35491747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma.
    Delfau-Larue MH; van der Gucht A; Dupuis J; Jais JP; Nel I; Beldi-Ferchiou A; Hamdane S; Benmaad I; Laboure G; Verret B; Haioun C; Copie-Bergman C; Berriolo-Riedinger A; Robert P; Casasnovas RO; Itti E
    Blood Adv; 2018 Apr; 2(7):807-816. PubMed ID: 29636326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
    Cottereau AS; El-Galaly TC; Becker S; Broussais F; Petersen LJ; Bonnet C; Prior JO; Tilly H; Hutchings M; Casasnovas O; Meignan M
    J Nucl Med; 2018 Apr; 59(4):589-595. PubMed ID: 28864629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma.
    Lu Z; Lin M; Downe P; Chong S; Ling S
    Ann Nucl Med; 2014 Oct; 28(8):805-11. PubMed ID: 25008291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.
    Cottereau AS; Versari A; Loft A; Casasnovas O; Bellei M; Ricci R; Bardet S; Castagnoli A; Brice P; Raemaekers J; Deau B; Fortpied C; Raveloarivahy T; Van Zele E; Chartier L; Vander Borght T; Federico M; Hutchings M; Ricardi U; Andre M; Meignan M
    Blood; 2018 Mar; 131(13):1456-1463. PubMed ID: 29437590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
    Schmitz C; Rekowski J; Müller SP; Hertenstein B; Franzius C; Ganser A; Bengel FM; Kroschinsky F; Kotzerke J; La Rosée P; Freesmeyer M; Hoeffkes HG; Hertel A; Behringer D; Mesters R; Weckesser M; Mahlmann S; Haberkorn U; Martens U; Prange-Krex G; Brenner W; Giagounidis A; Moeller R; Runde V; Sandmann M; Hautzel H; Wilop S; Krohn T; Dürk H; Heike M; Alashkar F; Brinkmann M; Trenn G; Wacker D; Kreisel-Büstgens C; Bernhard H; Heil G; Larisch R; Kurch L; Jöckel KH; Hoelzer D; Klapper W; Boellaard R; Dührsen U; Hüttmann A
    Hematol Oncol; 2020 Aug; 38(3):244-256. PubMed ID: 32067259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.
    Guo B; Tan X; Ke Q; Cen H
    PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal (18)F-FDG PET/CT in follicular lymphoma: A comparison of metabolic and clinical variables in the prognostic assessment.
    Jiménez Londoño GA; García Vicente AM; Poblete García VM; Amo-Salas M; Calle Primo C; Ibañez García Á; Martínez Sanchís B; López-Fidalgo JF; Solano Ramos F; Martínez Hellín A; Díaz Morfa M; Soriano Castrejón Á
    Rev Esp Med Nucl Imagen Mol; 2016; 35(5):298-305. PubMed ID: 27312693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.
    Trotman J; Luminari S; Boussetta S; Versari A; Dupuis J; Tychyj C; Marcheselli L; Berriolo-Riedinger A; Franceschetto A; Julian A; Ricard F; Guerra L; Haioun C; Biasoli I; Tilly H; Federico M; Salles G; Meignan M
    Lancet Haematol; 2014 Oct; 1(1):e17-27. PubMed ID: 27030064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
    Luminari S; Galimberti S; Versari A; Biasoli I; Anastasia A; Rusconi C; Ferrari A; Petrini M; Manni M; Federico M
    Haematologica; 2016 Feb; 101(2):e66-8. PubMed ID: 26471485
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.